Safety and efficacy of varenicline to reduce positive subjective effects produced by methamphetamine in methamphetamine-dependent volunteers

International Journal of Neuropsychopharmacology

Volumn 17, Issue 2, 2014, Pages 223-233

  Verrico, Christopher D ^a   Mahoney, James J ^a   Thompson Lake, Daisy G Y ^a   Bennett, Ryan S ^a   Newton, Thomas F ^a   De La Garza, Richard ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Acetylcholine; addiction; methamphetamine; varenicline

Indexed keywords

METHAMPHETAMINE; PLACEBO; VARENICLINE;

ABNORMAL DREAMING; ADULT; ALLERGY; ARTICLE; BODY PAIN; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; COMMON COLD SYMPTOM; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HEARTBURN; HUMAN; INSOMNIA; MALE; METHAMPHETAMINE DEPENDENCE; NAUSEA; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REINFORCEMENT; SMOKING; TOOTH PAIN;

ADULT; AMPHETAMINE-RELATED DISORDERS; BEHAVIOR, ADDICTIVE; BENZAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEADACHE; HUMANS; MALE; METHAMPHETAMINE; NICOTINIC AGONISTS; QUINOXALINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84891803974     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S146114571300134X     Document Type: Article

References (48)

1. Brensilver M, Heinzerling KG, Swanson AN, Telesca D, Furst BA, Shoptaw SJ (2013) Cigarette smoking as a target for potentiating outcomes for methamphetamine abuse treatment. Drug Alcohol Rev 32:96-99.
2. Cahill K, Stead LF, Lancaster T (2011) Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev (2) CD006103.
3. Cohen J (1988) Statistical power analysis for the behavioral science, 2nd edn. Hillsdale, NJ: L. Erlbaum Associates. Cruickshank CC, Dyer KR (2009) A review of the clinical pharmacology of methamphetamine. Addiction 104:1085-1099.
4. De La Garza R II, Mahoney JJ III, Culbertson C, Shoptaw S, Newton TF (2008a) The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers. Pharmacol, Biochem, Behav 89:200-208.
5. De La Garza R, Shoptaw S, Newton TF (2008b) Evaluation of the cardiovascular and subjective effects of rivastigmine in combination with methamphetamine in methamphetamine-dependent human volunteers. Int J Neuropsychopharmacol 11:729-741.
6. De La Garza R II, Zorick T, London ED, Newton TF (2010) Evaluation of modafinil effects on cardiovascular, subjective, and reinforcing effects of methamphetamine in methamphetamine-dependent volunteers. Drug and Alcohol Depend 106:173-180.
7. De La Garza R II, Newton TF, Haile CN, Yoon JH, Nerumalla CS, Mahoney JJ III, Aziziyeh A (2012) Rivastigmine reduces "likely to use methamphetamine" in methamphetaminedependent volunteers. Prog Neuropsychopharmacol Biol Psychiatry 37:141-146.
8. Dobbs LK, Mark GP (2008) Comparison of systemic and local methamphetamine treatment on acetylcholine and dopamine levels in the ventral tegmental area in the mouse. Neuroscience 156:700-711.
9. Dobbs LK, Mark GP (2012) Acetylcholine from the mesopontine tegmental nuclei differentially affects methamphetamine induced locomotor activity and neurotransmitter levels in the mesolimbic pathway. Behav Brain Res 226:224-234.
10. Elkashef AM, Rawson RA, Anderson AL, Li SH, Holmes T, Smith EV et al. (2008) Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology 33:1162-1170.
11. Fischman MW, Foltin RW (1991) Utility of subjective-effects measurements in assessing abuse liability of drugs in humans. Br J Addict 86:1563-1570.
12. Franklin T, Wang Z, Suh JJ, Hazan R, Cruz J, Li Y et al. (2011) Effects of varenicline on smoking cue-triggered neural and craving responses. Arch Gen Psychiatry 68:516-526.
13. Grace AA, Floresco SB, Goto Y, Lodge DJ (2007) Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends Neurosci 30:220-227.
14. Haney M, Collins ED, Ward AS, Foltin RW, FischmanMW(1999) Effect of a selective dopamine D1 agonist (ABT-431) on smoked cocaine self-administration in humans. Psychopharmacology 143:102-110.
15. Hart CL, Ward AS, Haney M, Foltin RW, Fischman MW (2001) Methamphetamine self-administration by humans. Psychopharmacology 157:75-81.
16. Hart CL, Haney M, Vosburg SK, Rubin E, Foltin RW (2008) Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 33:761-768.
17. Hiranita T, Nawata Y, Sakimura K, Anggadiredja K, Yamamoto T (2006) Suppression of methamphetamine-seeking behavior by nicotinic agonists. Proc Natl Acad Sci USA 103:8523-8527.
18. Hiranita T, Nawata Y, Sakimura K, Yamamoto T (2008) Methamphetamine- seeking behavior is due to inhibition of nicotinic cholinergic transmission by activation of cannabinoid CB1 receptors. Neuropharmacology 55:1300-1306.
19. Kish SJ, Kalasinsky KS, Furukawa Y, Guttman M, Ang L, Li L et al. (1999) Brain choline acetyltransferase activity in chronic, human users of cocaine, methamphetamine, and heroin. Mol Psychiatry 4:26-32.
20. Lee NK, Rawson RA (2008) A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug Alcohol Rev 27:309-317.
21. Longo M, Wickes W, Smout M, Harrison S, Cahill S, White JM (2010) Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. Addiction 105:146-154.
22. Mahoney JJ, Haile CN, Newton TF, Verrico CD, Shapiro B, De La Garza R (2013) A comparison of the subjective and cardiovascular effects produced by exposure to intravenous vs. smoked methamphetamine in the laboratory. Boston, MA: Abstract presented at the annual meeting of ASPET.
23. Mameli-Engvall M, Evrard A, Pons S, Maskos U, Svensson TH, Changeux JP et al. (2006) Hierarchical control of dopamine neuron-firing patterns by nicotinic receptors. Neuron 50:911-921.
24. McElhiney MC, Rabkin JG, Rabkin R, Nunes EV (2009) Provigil (modafinil) plus cognitive behavioral therapy for methamphetamine use in HIV+ gay men: a pilot study. Am J Drug Alcohol Abuse 35:34-37.
25. McGregor C, Srisurapanont M, Mitchell A, Wickes W, White JM (2008) Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual. J Subst Abuse Treat 35:334-342.
26. Newton TF, Roache JD, De La Garza R II, Fong T, Wallace CL, Li SH et al. (2005) Safety of intravenous methamphetamine administration during treatment with bupropion. Psychopharmacology 182:426-435.
27. Newton TF, Roache JD, De La Garza R II, Fong T, Wallace CL, Li SH et al. (2006) Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 31:1537-1544.
28. Ohmori T, Abekawa T, Koyama T (1995) Scopolamine prevents the development of sensitization to methamphetamine. Life Sci 56:1223-1229.
29. Omelchenko N, Sesack SR (2006) Cholinergic axons in the rat ventral tegmental area synapse preferentially onto mesoaccumbens dopamine neurons. J Comp Neurol 494:863-875.
30. Perez-Reyes M, White WR, McDonald SA, Hill JM, Jeffcoat AR, Cook CE (1991) Clinical effects of methamphetamine vapor inhalation. Life Sci 49:953-959.
31. Plebani JG, Lynch KG, Yu Q, Pettinati HM, O'Brien CP, Kampman KM (2012) Results of an initial clinical trial of varenicline for the treatment of cocaine dependence. Drug Alcohol Depend 121:163-166.
32. Rau KS, Birdsall E, Hanson JE, Johnson-Davis KL, Carroll FI, Wilkins DG et al. (2005) Bupropion increases striatal vesicular monoamine transport. Neuropharmacology 49:820-830.
33. Rush CR, Stoops WW, Lile JA, Glaser PE, Hays LR (2011) Subjective and physiological effects of acute intranasal methamphetamine during d-amphetamine maintenance. Psychopharmacology 214:665-674.
34. Shearer J, Darke S, Rodgers C, Slade T, van Beek I, Lewis J et al. (2009) A double-blind, placebo-controlled trial of modafinil (200 mg/day). for methamphetamine dependence. Addiction 104:224-233.
35. Shoptaw S, Heinzerling KG, Rotheram-Fuller E, Steward T, Wang J, Swanson AN et al. (2008) Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend 96:222-232.
36. Siegal D, Erickson J, Varoqui H, Ang L, Kalasinsky KS, Peretti FJ et al. (2004) Brain vesicular acetylcholine transporter in human users of drugs of abuse. Synapse 52:223-232.
37. Sofuoglu M, Brown S, Babb DA, Pentel PR, Hatsukami DK (2000) Carvedilol affects the physiological and behavioral response to smoked cocaine in humans. Drug Alcohol Depend 60:69-76.
38. Substance Abuse and Mental Health Services Administration (2005) The DASIS report: smoked methamphetamine/amphetamines 1992-2002. Rockville, MD: Office of Applied Studies, NHSDA, DHHS. http://oassamhsagov/2k4/methSmoked/ methSmokedhtml.
39. Substance Abuse and Mental Health Services Administration (2011) Treatment episode data set (TEDS) 1999-2009.
40. Rockville, MD: National Admissions to Substance Abuse Treatment Services, DASIS Series: S-56, HHS Publication No. (SMA) 11-4646.
41. Substance Abuse and Mental Health Services Administration (2012) Results from the 2011 national survey on drug use and health: summary of national findings. Rockville, MD: NSDUH Series H-44, HHS Publication No (SMA)12-4713.
42. Taguchi K, Atobe J, Kato M, Chuma T, Chikuma T, Shigenaga T et al. (1998) The effect of methamphetamine on the release of acetylcholine in the rat striatum. Eur J Pharmacol 360:131-137.
43. Tiihonen J, Kuoppasalmi K, Fohr J, Tuomola P, Kuikanmaki O, Vorma H et al. (2007) A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatry 164:160-162.
44. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D et al. (2001) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158:377-382.
45. Volkow ND, Wang GJ, Ma Y, Fowler JS, Wong C, Ding YS et al. (2005) Activation of orbital and medial prefrontal cortex by methylphenidate in cocaine-addicted subjects but not in controls: relevance to addiction. J Neurosci 25:3932-3939.
46. Volkow ND, Fowler JS, Logan J, Alexoff D, ZhuW, Telang F et al. (2009) Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 301:1148-1154.
47. Wang GJ, Smith L, Volkow ND, Telang F, Logan J, Tomasi D et al. (2012) Decreased dopamine activity predicts relapse in methamphetamine abusers. Mol Psychiatry 17:918-925.
48. Zorick T, Sevak RJ, Miotto K, Shoptaw S, Swanson AN, Clement C et al. (2009) Pilot safety evaluation of varenicline for the treatment of methamphetamine dependence. J Exp Pharmacol 2010:13-18.